Online inquiry

IVTScrip™ mRNA-Anti-LAG3, BMS-986016(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ4623MR)

This product GTTS-WQ4623MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets LAG3 gene. The antibody can be applied in Non-Hodgkin's lymphoma (NHL) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_002286.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3902
UniProt ID P18627
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-LAG3, BMS-986016(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ4623MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9070MR IVTScrip™ mRNA-Anti-IGF1R, IMC-A12(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA IMC-A12
GTTS-WQ12035MR IVTScrip™ mRNA-Anti-NRP1, MNRP1685A(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MNRP1685A
GTTS-WQ3323MR IVTScrip™ mRNA-Anti-VEGFA, AT-001(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AT-001
GTTS-WQ7434MR IVTScrip™ mRNA-Anti-ITGA2, GBR500(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA GBR500
GTTS-WQ5111MR IVTScrip™ mRNA-Anti-CD52, Campath-1H(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA Campath-1H
GTTS-WQ4547MR IVTScrip™ mRNA-Anti-CXCR4, BMS-936564(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BMS-936564
GTTS-WQ7162MR IVTScrip™ mRNA-Anti-CTGF, FG-3019(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA FG-3019
GTTS-WQ15117MR IVTScrip™ mRNA-Anti-ERBB2, SYD985(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA SYD985
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW